Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia

This study evaluated the use of topical tofacitinib 2% cream in 41 patients with lichen planopilaris (LPP) and/or frontal fibrosing alopecia (FFA) over a minimum of 3 months. The results showed a significant reduction in disease activity, with a 48% decrease in the Lichen Planopilaris Activity Index (LPPAI) scores. Improvement or stabilization of the frontotemporal hairline was observed in 92.1% of patients with FFA or FFA/LPP overlap. Adverse events were minimal, with scalp irritation in 4.9% and acne in 2.4% of patients. The study suggests that topical tofacitinib is a safe and effective alternative for patients where systemic therapy is not suitable, although further controlled trials are needed to confirm these findings.